Judge: branded companies may be liable for generic versions

Share this article:
Philadelphia Common Pleas judge Mark Bernstein has ruled that branded drug companies may be liable for money spent on the generic version of their drugs when it is marketed for off-label uses. He ordered that claims against Warner-Lambert and Pfizer involving a generic version of Neurontin that was produced by a third-party manufacturer and marketed for off-label uses could continue to trial.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.